ProQR Therapeutics N.V. diskutieren
ProQR Therapeutics N.V.
WKN: A12B97 / Symbol: PRQR / Name: ProQR / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
1,62 €
-1,64 %
ProQR Therapeutics (NASDAQ: PRQR) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $5.00 price target on the stock.
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics (NASDAQ: PRQR) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $15.00 to $9.00. They now have an "outperform" rating on the stock.
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics N.V. (NASDAQ: PRQR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $8.00 price target on the stock.
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics N.V. (NASDAQ: PRQR) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics (PRQR) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $9.00 price target on the stock.
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics (PRQR) had its "buy" rating reaffirmed by Chardan Capital. They now have a $4.00 price target on the stock.
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics (PRQR) had its price target lowered by JonesTrading from $11.00 to $10.00. They now have a "buy" rating on the stock.
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics (PRQR) had its "buy" rating reaffirmed by HC Wainwright.
Ratings data for PRQR provided by MarketBeat
Neueste Beiträge
TD_Securities in Talon Metals Corp. diskutieren